BECTON, DICKINSON AND COMPANY Becton, Dickinson and Company Stock
Equities
BDX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 232 USD | +2.29% |
|
+1.39% | -4.86% |
Financials (USD)
| Sales 2024 * | 20.24B | Sales 2025 * | 21.43B | Capitalization | 67.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.11B | Net income 2025 * | 2.48B | EV / Sales 2024 * | 3.96 x |
| Net Debt 2024 * | 13.13B | Net Debt 2025 * | 10.8B | EV / Sales 2025 * | 3.63 x |
| P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
28.8
x | Employees | 73,000 |
| Yield 2024 * |
1.62% | Yield 2025 * |
1.66% | Free-Float | 77.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Becton, Dickinson and Company
More recommendations
More press releases
| 1 day | +2.29% | ||
| 1 week | +1.39% | ||
| 1 month | -3.49% | ||
| 3 months | -1.42% | ||
| 6 months | -2.64% | ||
| Current year | -4.86% |
1 week
224.00
232.21
1 month
224.00239.57
Current year
224.00249.89
1 year
224.00287.32
3 years
215.90287.32
5 years
197.75287.32
10 years
112.15287.32
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Polen
CEO | Chief Executive Officer | 50 | 08-12-31 |
| Director of Finance/CFO | 52 | 21-09-05 | |
| Chief Tech/Sci/R&D Officer | 48 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bertram Scott
BRD | Director/Board Member | 73 | 02-09-23 |
Catherine Burzik
BRD | Director/Board Member | 73 | 13-01-28 |
| Director/Board Member | 69 | 10-07-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.40% | 254 M€ | +13.69% | - | |
| 2.78% | 2 M€ | -.--% | - | |
| 2.47% | 6 M€ | +16.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 232 | +2.29% | 4,733,925 |
| 24-05-30 | 226.8 | +0.76% | 1,691,719 |
| 24-05-29 | 225.1 | -0.76% | 2,680,574 |
| 24-05-28 | 226.8 | -0.87% | 1,452,801 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
2024-06-09
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232
USD
Average target price
278.7
USD
Spread / Average Target
+20.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.86% | 67.04B | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.28% | 47.23B | |
| +10.32% | 44.62B | |
| +9.19% | 42.5B | |
| +16.46% | 25.22B | |
| -5.88% | 24.14B | |
| -5.38% | 23.69B | |
| +1.38% | 22.04B |
- Stock Market
- Equities
- BDX Stock
